Clarifying menopause status and measurement of ER/PgR is mandated for all cases of invasive breast cancer, as recently outlined in the 5th ESMO International Consensus for advanced and local breast cancers in addition to the recent RxPONDER trial [3,40,41]. The gene discussed is ESR1; the disease is invasive breast carcinoma.